• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

    10/16/25 5:35:18 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRON alert in real time by email
    • Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP
    • The CNPV program is designed to reduce the drug application review process to 1-2 months

    WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it received a Commissioner's National Priority Voucher (CNPV) from the U.S. Food and Drug Administration (FDA) for bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). Disc submitted a New Drug Application (NDA) to the FDA for bitopertin for patients aged 12 years and older with EPP following the FDA's accelerated approval pathway in September 2025. Bitopertin has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.

    "We are honored to have received this voucher which underscores the potential impact of bitopertin and reinforces the immense need EPP patients have for a new therapy that may address the underlying cause of their disease," said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. "We are grateful to the FDA for implementing this innovative new voucher program and we look forward to working closely with the Agency to bring bitopertin to patients as soon as possible. All of this would not be possible without collaboration from the EPP patient and caregiver community, and we thank them for their contributions."

    The Commissioner's National Priority Voucher program, announced in June 2025, is designed to accelerate the development and review of certain drugs aligned with US national health priorities by offering the opportunity to reduce drug application review times to 1-2 months. Additionally, companies selected for the program will be issued a voucher entitling them to benefits including enhanced communications and rolling review to allow for shortened review time.

    Erythropoietic protoporphyria is a rare, debilitating and potentially life-threatening disease caused by mutations that affect heme biosynthesis, resulting in the accumulation of a toxic, photoactive intermediate called protoporphyrin IX (PPIX). This causes severe reactions when patients are exposed to sunlight, characterized by excruciating pain, edema, burning sensations and potential blistering and disfigurement. PPIX also accumulates in the hepatobiliary system and can result in complications including gallstones, cholestasis, and liver damage in 20-30% of patients and in extreme cases liver failure. Current standard of care involves extreme measures to avoid sunlight, including restricting outdoor activities to nighttime, use of protective clothing and opaque shields, and pain management. This has a significant impact on the psychosocial development, quality of life, and daily activities of patients, particularly in young children and families.

    About Bitopertin

    Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is developing bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, an open-label extension HELIOS trial, and the confirmatory Phase 3 double-blind, placebo-controlled APOLLO trial.

    Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.

    About Disc Medicine

    Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

    Disc Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: Disc's expectations with respect to the registrational pathway for bitopertin, including the timeline for the FDA's review of the NDA submission and the potential benefits of the Commissioner's National Priority Voucher program; and the potential of bitopertin as a therapeutic drug. The use of words such as, but not limited to, "believe," "expect," "estimate," "project," "intend," "future," "potential," "continue," "may," "might," "plan," "will," "should," "seek," "anticipate," or "could" or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc's current beliefs, expectations and assumptions regarding the future of Disc's business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc's capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc's product candidates; Disc's plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc's planned preclinical studies and clinical trials; the timing of the availability of data from Disc's clinical trials; Disc's ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc's preclinical studies and clinical trials and the risk that the results of Disc's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; the content and timing of decisions made by the FDA and other regulatory authorities; and the other risks and uncertainties described in Disc's filings with the SEC, including in the "Risk Factors" section of Disc's Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement,

    Media Contact

    Alexandra Phelps

    Pinkston

    [email protected]

    Investor Relations Contact

    Christina Tartaglia

    Precision AQ

    [email protected] 



    Primary Logo

    Get the next $IRON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRON

    DatePrice TargetRatingAnalyst
    7/21/2025$86.00Buy
    Truist
    7/3/2025$85.00Overweight
    Morgan Stanley
    6/11/2025$89.00Strong Buy
    Raymond James
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten offering of $220.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, of which $200.0 million of shares are to be offered by Disc and $20.0 million of shares are to be offered by AI DMI LLC (the Selling Stockholder). In addition, the Selling Stockholder int

    10/20/25 7:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

    Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National Priority Voucher (CNPV), a program designed to shorten the expected NDA review period to 1-2 monthsAcceleration of ongoing efforts to support the potential earlier approval and commercialization of bitopertin for EPP in the US, expected in late 2025 or early 2026Plans to advance DISC-0974 for anemia of myelofibrosis (MF) and DISC-3405 for polycythemia vera (PV) deeper into development and to continue exploring potential role of hepcidin in additional indicationsStrong financial position ending

    10/20/25 6:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

    WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025. "We look forward to returning to Kidney Week this year, where we will provide an update from our Phase 1b study of DISC-0974 in NDD-CKD patients with anemia," said John Quisel, J.D., Ph.D., President and Chief Executive Officer o

    10/17/25 9:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 8:00:05 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:27:54 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:19:39 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin sold $8,045,252 worth of shares (93,585 units at $85.97) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    10/17/25 4:41:42 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $6,312,501 worth of shares (90,000 units at $70.14) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    10/9/25 4:07:04 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gemayel Georges

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    9/18/25 5:03:37 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Disc Medicine with a new price target

    Truist initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $86.00

    7/21/25 8:34:40 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Disc Medicine with a new price target

    Morgan Stanley resumed coverage of Disc Medicine with a rating of Overweight and set a new price target of $85.00

    7/3/25 8:01:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Disc Medicine with a new price target

    Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00

    6/11/25 7:53:18 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    SEC Filings

    View All

    SEC Form 424B5 filed by Disc Medicine Inc.

    424B5 - Disc Medicine, Inc. (0001816736) (Filer)

    10/20/25 7:09:09 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Disc Medicine, Inc. (0001816736) (Filer)

    10/20/25 6:38:05 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    10/17/25 5:23:27 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Leadership Updates

    Live Leadership Updates

    View All

    Disc Medicine Appoints Nadim Ahmed to its Board of Directors

    WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological

    7/14/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

    Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

    11/12/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

    WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

    10/23/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 4:33:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Disc Medicine Inc.

    SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

    11/8/24 10:52:39 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Financials

    Live finance-specific insights

    View All

    Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

    Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

    6/12/25 7:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

    Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

    5/14/25 9:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

    Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

    1/21/25 7:45:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care